| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-20 |
| filingDate |
2015-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a51744918350003a100576371094499 |
| publicationDate |
2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015205901-A |
| titleOfInvention |
Chlorous acid in the treatment of neurodegenerative diseases |
| abstract |
A novel therapeutic method for amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) is provided. Macrophage-related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease in a subject by administering an amount of chlorous acid effective to reduce blood immune cell activation. (AD), or a therapeutic method of treating multiple sclerosis (MS). A method wherein chlorous acid is administered in the form of a matrix of chlorite ions such as tetrachlorodecaoxygen or in the form of a pharmaceutically acceptable chlorite such as sodium chlorite. A therapeutic method for monitoring treatment by evaluating blood immune cell activation before and after treatment. [Selection] Figure 6 |
| priorityDate |
2004-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |